5-methoxy-2,3-dimethyl-quinoxaline-1,4-dioxide | 31983-97-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-methoxy-2,3-dimethyl-quinoxaline-1,4-dioxide
• 英文别名: 5-Methoxy-2,3-dimethyl-chinoxalin-1,4-dioxid；8-Methoxy-2,3-dimethyl-4-oxidoquinoxalin-1-ium 1-oxide
• CAS: 31983-97-8
• 化学式: C₁₁H₁₂N₂O₃
• 分子量: 220.228
• InChiKey: KHWIVNHEUDJSAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  55.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-methoxy-2,3-dimethyl-quinoxaline-1,4-dioxide 在 三氯化铝 、 苯 作用下， 生成 2,3-dimethyl-1-oxy-quinoxalin-5-ol
  参考文献：
  名称：

  404.喹喔啉N-氧化物。第五部分其他Bz取代的衍生物

  摘要：

  DOI：

  10.1039/jr9560002058
• 作为产物：
  描述：

  2,3-二氨基苯甲醚 在 过氧乙酸 、 溶剂黄146 作用下， 生成 5-methoxy-2,3-dimethyl-quinoxaline-1,4-dioxide
  参考文献：
  名称：

  Landquist; Stacey, Journal of the Chemical Society, 1953, p. 2822,2827

  摘要：

  DOI：

文献信息

• Substituted phenazines and methods of treating cancer and bacterial diseases
  申请人：Rongved Pål

  公开号：US11046678B2

  公开（公告）日：2021-06-29

  Compounds of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the compounds, and methods of treatment using the compounds.

  式 (Ia) 或 (Ib) 的化合物，或其药学上可接受的盐、 包含这些化合物的药物组合物，以及使用这些化合物的治疗方法。
• MUSATOVA I. S.; ELINA A. S.; TRIFONOVA E. A.; PADEJSKAYA E. N.; NOVITSKAY+, XIM.-FARMATS. ZH., 1979, 13, HO 7, 64-67
  作者：MUSATOVA I. S.、 ELINA A. S.、 TRIFONOVA E. A.、 PADEJSKAYA E. N.、 NOVITSKAY+

  DOI：——

  日期：——
• N-OXIDE HETEROCYCLES FOR USE IN THE TREATMENT OF CANCER AND BACTERIAL DISEASES
  申请人：Rongved, Pål

  公开号：EP3555052A1

  公开（公告）日：2019-10-23
• COMPOUNDS
  申请人：RONGVED Pål

  公开号：US20200095237A1

  公开（公告）日：2020-03-26

  The invention provides compounds of general formula (I′), and their pharmaceutically acceptable salts: wherein: Z is a group having the formula: -T-S-A-Y in which: T is a group selected from —O—, —NH—, —S—, —(XCR 7 R 8 )— (where R 7 and R 8 is independently —H or C 1-3 alkyl and X is selected from from —O—, —NH—, —S—); S is —(C═O)—, —(SO 2 )—, —(PO 2 )—; A, —O—, —NH—, —S— or —NH(CO)—, —(CR 7 R 8 X)— (where R 7 and R 8 is independently —H or C 1-3 alkyl and X is selected from from —O—, —NH—, —S—), -T-S-A- is a group susceptible to hydrolytic and/or enzymatic cleavage in vivo to leave a group selected from —OH, —NH 2 , —SH, —COOH, —CONH 2 , —O—(CR 7 R 8 )—COOH and —(CR 7 R 8 )—CONH 2 ; Y is one or more targeting groups or a lipophilic or hydrophilic group affecting the solubility in water and the biodistribution in a living organism or a living cell; R 1 -R 6 are independently selected from hydrogen, halogen (e.g. F, Cl, Br, I), lower alkyl (e.g. C 1-6 alkyl), optionally substituted with an acidic group which is —COOH, —SO 3 H, —PO 3 H 2 or —B(OH) 2 . Such compounds find particular use as anti-neoplastic and anti-infective agents.
• SUBSTITUTED PHENAZINES AND METHODS OF TREATING CANCER AND BACTERIAL DISEASES
  申请人：Rongved Pål

  公开号：US20210292313A1

  公开（公告）日：2021-09-23

  A combination product comprising a carbapenem and a compound of formula (I′), or a pharmaceutically acceptable salt thereof: a pharmaceutical composition comprising the combination product; and methods of treating bacterial or fungal infections using the combination product and pharmaceutical composition.